Early efforts by states drive value with Medicaid ACOs, coordinated care.
HEALTHCARE'S DIFFICULT times call for bold steps in value strategies, such as patient-centered medical homes, shared-savings and others.
In addition to the five states that are moving forward on Medicaid ACOs-Colorado, Minnesota, New Jersey, Oregon and Utah-another five could commit within the next six months, says Tricia McGinnis, senior program officer at the Center for Health Care Strategies (CHCS). The not-for-profit health policy resource center works with state and federal agencies to improve the quality of Medicaid programs and currently is working with 39 states.
"Data is a huge component of success," McGinnis says. "Providers often don't have that line of sight into the care they deliver that good data can bring."
Four out of five also have an active managed-care organization in the mix, according to CHCS research by McGinnis and policy analyst David Marc Small. Colorado and Oregon are developing hybrid payer/provider-led programs, while Minnesota has a combination of governance. Utah is exploring the payer-led model for its program in four populous counties around Salt Lake City.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More
Doing More and Saving More with Primary in Home Care
September 1st 2021In this week’s episode of Tuning In to the C-Suite podcast, MHE Associate Editor Briana Contreras interviewed VillageMD’s Senior Medical Director of Village Medical at Home, Dr. Tom Cornwell. Dr. Cornwell discussed the main benefits of primary care at home, which includes the benefit of cost savings for patients, maintaining control of hospital readmissions and others. Dr. Cornwell also noted what has changed in the industry of at-home care and if there has been interest from payers like insurance companies and medicare in the service.
Listen
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
Read More